Flora Growth Corp. (FLGC)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Flora Growth Corp. (FLGC) Reports Q3 Loss, Misses Revenue Estimates
Flora Growth Corp. (FLGC) came out with a quarterly loss of $4.93 per share versus the Zacks Consensus Estimate of a loss of $2.13. This compares to a loss of $9.38 per share a year ago.
Flora Growth Corp. (FLGC) Reports Q2 Loss, Tops Revenue Estimates
Flora Growth Corp. (FLGC) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.22 per share a year ago.
Flora Growth Corp. Forecasted to Earn Q2 2024 Earnings of ($0.02) Per Share (NASDAQ:FLGC)
Flora Growth Corp. (NASDAQ:FLGC – Free Report) – Stock analysts at Roth Capital raised their Q2 2024 EPS estimates for shares of Flora Growth in a report released on Thursday, May 16th. Roth Capital analyst W. Kirk now anticipates that the company will earn ($0.02) per share for the quarter, up from their prior forecast of ($0.10). The consensus estimate for Flora Growth’s current full-year earnings is ($0.39) per share. Roth Capital also issued estimates for Flora Growth’s Q3 2024 earnings at ($0.01) EPS, Q4 2024 earnings at ($0.01) EPS, FY2024 earnings at ($0.30) EPS and FY2025 earnings at $0.48 EPS. Separately, Roth Mkm restated a “buy” rating and set a $6.00 price objective (down previously from $7.00) on shares of Flora Growth in a research report on Thursday. Check Out Our Latest Analysis on FLGC Flora Growth Trading Up 0.8 % Shares of Flora Growth stock opened at $1.31 on Monday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.79 and a current ratio of 1.13. Flora Growth has a one year low of $0.63 and a one year high of $5.48. The firm has a fifty day moving average of $1.67 and a two-hundred day moving average of $1.34. Flora Growth (NASDAQ:FLGC – Get Free Report) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). The firm had revenue of $18.03 million for the quarter, compared to analysts’ expectations of $19.04 million. Flora Growth had a negative return on equity of 144.44% and a negative net margin of 75.95%. Insider Activity In related news, CEO Clifford Starke purchased 526,315 shares of the business’s stock in a transaction dated Monday, April 8th. The stock was acquired at an average price of $1.90 per share, for a total transaction of $999,998.50. Following the acquisition, the chief executive officer now directly owns 565,714 shares of the company’s stock, valued at approximately $1,074,856.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 17.60% of the company’s stock. Institutional Investors Weigh In On Flora Growth A hedge fund recently bought a new stake in Flora Growth stock. Armistice Capital LLC acquired a new stake in Flora Growth Corp. (NASDAQ:FLGC – Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 447,623 shares of the company’s stock, valued at approximately $519,000. Armistice Capital LLC owned about 5.45% of Flora Growth at the end of the most recent quarter. 36.01% of the stock is owned by institutional investors. Flora Growth Company Profile (Get Free Report) Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products.
Flora Growth Corp. (FLGC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Flora Growth Corp. ever had a stock split?
Flora Growth Corp. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Daniel Reis-Faria CEO | NASDAQ (CM) Exchange | 339764300 CUSIP |
| CA Country | 64 Employees | - Last Dividend | 4 Aug 2025 Last Split | 11 May 2021 IPO Date |
Overview
Flora Growth Corp. is a prominent entity in the global cannabis industry, founded in 2019 and headquartered in Fort Lauderdale, Florida. The company operates through a multifaceted approach, encompassing the cultivation, development, and distribution of medicinal cannabis and its derivative products across the globe. Flora Growth's operations are strategized across three main segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. This structure enables the company to cover a broad spectrum of the cannabis market, including medicinal-grade cannabis flower, cannabis-derived medical and wellness products, as well as pharmaceuticals designed to treat a wide array of health conditions. With a commitment to quality and innovation, Flora Growth leverages its diverse portfolio to meet the evolving needs of consumers and patients worldwide.
Products and Services
Flora Growth Corp. offers a wide range of products and services, tailored to cater to the medicinal, wellness, and recreational needs of its diverse clientele. Its product lineup encompasses:
- Medicinal-Grade Cannabis Flower & Derivatives: Cultivated with strict adherence to quality standards, these products are designed for medical use, providing patients with effective, natural solutions for their health needs.
- Food and Beverage: Incorporating cannabinoids such as cannabidiol (CBD) into various food and beverage products, Flora Growth offers a discreet and enjoyable way to consume cannabis for both medicinal and wellness purposes.
- Nutraceuticals: These are health-enhancing products derived from cannabis, designed to supplement the diet and provide health benefits beyond basic nutrition.
- Cannabis Accessories and Technology: Flora Growth provides a range of accessories and technological solutions for cannabis consumption, including personal storage and travel accessories designed for both vape and dry herbs enthusiasts.
- Personal Care and Wellness Products: From topicals to tinctures, and vape products, the company offers a variety of CBD-derived items that cater to personal care and wellness needs. These products combine the therapeutic properties of cannabis with everyday personal care.
- Pharmaceuticals: Flora Growth also engages in the production and distribution of pharmaceutical goods incorporating medicinal cannabis. These products target a variety of health indications, including but not limited to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. By leveraging the medical potential of cannabis, Flora Growth aims to innovate in the pharmaceutical industry and provide effective remedies for various health challenges.
The company strategically markets its offerings under reputable brands such as JustCBD, Vessel, and Phatebo, ensuring that consumers and patients receive products of the highest quality, backed by Flora Growth's commitment to excellence.
Contact Information
